Expression of tissue type plasminogen activator and type 1 plasminogen activator inhibitor, and persistent fibrin deposition in chronic renal allograft failure  by Wang, Yiming et al.
Kidney International, Vol. 52 (1997), pp. 371—377
CELL BIOLOGY - IMMUNOLOGY - PATHOLOGY
Expression of tissue type plasminogen activator and type 1
plasminogen activator inhibitor, and persistent fibrin deposition
in chronic renal allograft failure
YIMING WANG, JULIAN R. PRATT, BARRIEHARTLEY, BERYL EvANs, LYNA Z1w.1G, and STEVEN H. SACKS
Departments of Nephrology and Transplantation, Histopathology, United Medical & Dental School of Guy's & St. Thomas' Hospital,
London, and Institute of Molecular Medicine, John Radcliffe Hospita4 Oxford, England, United Kingdom
Expression of tissue type plasminogen activator and type 1 plasmino-
gen activator inhibitor, and persistent fibrin deposition in chronic renal
allograft failure. Persistent fibrin deposition has been observed in kidneys
undergoing chronic rejection, and has been suggested to contribute to the
obliteration of the vasculature in these grafts. The mechanisms leading to
it are not clear. Fibrinolysis, the process to remove fibrin in tissues, is
initiated by tissue type plasminogen activator (tPA) and suppressed by
type 1 plasminogen activator inhibitor (PAL-i). To investigate their roles
in chronic rejection and fibrin deposition, we serially examined the
expression of tPA and PAl-I in an unmodified chronic rejection model,
using a Fisher 344 to Lewis rat renal transplant, at 0, 2, 4, 6, 10, 12, 16 and
20 weeks post-transplantation (N = 4 rats/time point in each group). We
also analyzed fibrin deposition and the development of chronic changes in
the grafts. Our results show that tPA was up-regulated only in the acute
phase of rejection (P < 0.05), whereas PAl-i was induced and persistently
expressed during the progressive phase of chronic rejection, together with
persistent fibrin deposition in the grafts. Immunohistochemistry showed
PAl-i was mainly localized to the damaged/proliferative vascular intima.
The results suggest that persistent induction of PAl-i may be responsible
for the continuance of fibrin deposition, which is associated with irrevers-
ible damage and chronic graft loss.
Despite the improvements in immunosuppression and patient
care, the rate of chronic rejection of renal grafts has not changed
significantly since the beginning of clinical transplantation several
decades ago. Chronic rejection has now become one of the major
causes for the steady loss of grafts [11.
One of the major histopathological changes of chronically
rejected grafts is the gradual narrowing and eventual obliteration
of hollow structures, including vessels, bronchioles, or bile ducts
[1]. In renal grafts, these changes mainly occur in the arteries,
causing ischemic changes in the areas supplied by the blood
vessels, and eventually leading to the loss of parenchymal tissues.
The narrowing and obstruction of the lumina of the blood vessels
mainly arises from hyperplasia of the intima, due to continuing
stimulation and damage to the vascular endothelium, with fibrin,
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complement and immunoglobulin depositions in the vesel walls
leading to subsequent fibrosis [1—3].
Persistent fibrin deposition in small or large vessels and in the
surrounding tissues during the periods of the gradual decline of
graft function has been observed by several groups, even in the
absence of evidence of acute rejection episodes [4—9]. This blocks
small vessels, causes endothelial damage, and stimulates scarring
in the affected tissues, and therefore contributes to the narrowing
and obliteration of these structures, and so to the development of
irreversible damage in the grafts [2, 3, 10].
In normal tissues, insoluble fibrin can be readily degraded and
removed by fibrinolysis [10—13]. The fibrinolytic cascade is initi-
ated by the plasminogen activators, and counter-regulated by the
plasminogen activator inhibitors [12, 13]. Tissue type plasminogen
activator (tPA) is a fast acting pro-fibrinolysis mediator, and its
counterpart, type 1 plasminogen activator inhibitor (PAl-i), is an
effective and fast acting pro-hemostasis mediator [12, 13]. In a
previous study [14] using human tissue, we showed that there is
up-regulation of PAl-i in several cases of irreversibly rejected
renal grafts. This suggests that the up-regulation of PAl-i may be
responsible for the persistence of fibrin in the grafts. To test this
hypothesis and to further study the dynamic expression of tPA and
PAT-i and their relationship to the development of chronic
changes in the grafts, we used an unmodified rat model with a long
surviving but gradually declining allograft function, and serially
monitored the expression of tPA and PAT-i, and fibrin deposition,
in relation to the development of the irreversible changes in the
grafts.
METHODS
Animal model
Lewis (RT11) and Fisher F344 (RTi) male rats, 200 to 250 g,
were obtained from Harlan Olac (Bicester, UK), and maintained
in the Biological Services Division of UMDS (Guy's Hospital,
London, UK), with alternative light and dark cycles, and fed on a
standard rat diet.
The chronic rejection model was established using the methods
described by Tilney et al [5] and Tanabe et al [15]. Kidneys of
Fisher 344 were transplanted into Lewis recipients in the allograft
group orthotopically, and of Lewis donors into Lewis recipients in
the isograft group. The native kidneys were removed at 14 days
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Table 1. cDNA probes used in the RNase protection assays
Protected
region Promoter
Ligation
site(s)
EcoRI
Pst 1/Eco RV
Eco RI/Barn HI
pGEM I
Blue KS
Blue KS
Cutting
enzyme
M31184 Hind III
M24067 Barn HI
M17701 XbaI
Table 2. Antibodies used in the immunohistochemistry
Antibody Specifity Source Species Dilutions Negative control
tPA Human/rat American Diagnostic Inn
CT, USA
Goat 1/250 Normal goat serum
PAl-i Rat American Diagnostic Inn
CT, USA
Rabbit 1/200 Normal rabbit serum
Fibrin Fibrin-like f3 peptide Serotec
Oxford, UK
Monoclonal 1/50 PBS
post-transplantation. No immunosuppression was used. Four rats
from each of the allograft and isograft groups were sacrificed at 2,
4, 6, 10, 12, 16 and 20 weeks post-transplantation. Four normal
untreated rats were also used as controls. At the time of sacrifice,
a terminal blood sample was obtained for serum creatinine
analysis and the grafts were removed.
Histopathology
Tissues from renal grafts and normal kidneys were fixed in 10%
formalin overnight, and processed and embedded in paraffin by
conventional methods. Sections 2 tm thick were cut, and stained
with hematoxylin and eosin (HE), periodic acid-Schiff (PAS),
martius scarlet blue (MSB) and silver methenamine. The slides
were examined under light microscopy.
Graft function
Serum creatinine was measured by a standard method in our
service laboratory.
Quantification of tPA and PM-i mRNA expression in the
grafts
RNA was extracted and purified from each graft or normal
kidney by the methods previously described [16]. tPA eDNA
probe used for this assay was a gift from Professor Tor Ny [17],
and PAl-i eDNA probe was from Professor Gelerhter and
Dr. J Heaton [18]. The rat glyceraldehyde-3-phosphate-dehydro-
genase (GAPDH) probe used as the internal control was con-
structed in our laboratory. The details of the probes are listed in
Table 1.
RNase protection assays [19J were used to analyze tPA and
PAl-i mRNA in the grafts. The probes were labeled with 32P by
in vitro transcription, and then hybridized with 10 j.tg total RNA
from each kidney at 45C overnight. The hybridized RNA was
then digested with RNase A and RNase T1, and purified by
phenol extraction and ethanol precipitation. The purified hybrids
were separated by polyacrylamide gel electrophoresis. The gels
were dried and exposed to Fuji X-ray film for I to 30 days. The
intensity of the bands were measured by a Bio-Rad densitometer.
The quantity of tPA and PAT-i mRNA were expressed as their
ratio to rat GAPDH in the same lane. In the negative control
group, tRNA (Boehringer), instead of the total RNA extracted
from the tissue, was assayed for tPA and PAl-i mRNA in the
exactly same manner as the test groups.
Immunohistochemistry
The localization of tPA in the grafts was studied by the method
described by Sumi et al [20] in frozen tissue. The staining of PAl-i
and fibrin employed an avidin-biotin-peroxidase complex (ABC)
method [21] in formalin fixed tissue. The details are listed in
Table 2.
Statistical analysis
The Kruskal-Wallis test was used to analyze the differences in
tPA and PAl-i expression, and serum creatinine levels within the
same group. The differences between the two groups (allo- vs.
isografts including normal rats) were analyzed by Mann-Whitney
U-test (unpaired).
RESULTS
Animal survival
Eighty percent of the rats in the allograft group survived until
the dates of sacrifice, although with histopathological changes and
deteriorating renal function in the later stages. The rats in the
isograft group appeared as normal and survived the entire period
observed.
Histopathological changes
Allogrft group. At two weeks there were florid inflammatory
changes in the grafts, comprised of a severe mononuclear cell
infiltrate around the big vessels, spreading into the interstitium
and crossing tubular basement membranes, and disrupting graft
structures (Fig. 1). Glomeruli were slightly enlarged with infiltrat-
ing mononuclear cells. Vascular endothclial cells were prominent,
and marginating mononuclear cells could be seen (Fig. 2). The
walls of these arteries and arterioles were infiltrated by these cells.
Some vessels had fibrinoid changes. Microthrombi were present in
some glomerular loops and also in the interstitial capillaries.
Interstitial edema and tubular epithelial attenuation were also
seen.
Gene Length
tPA 476 400 T7
PAT-I 407 323 T3
GAPDH 350 258 T3
Accession
Vector no.
Wang et a!: tPA, PAl-I and fibrin in chronic rejection 373
Fig. 1. Allograft, two weeks post-transplantation, section stained with
hematoxylin and eosin. There is widespread mononuclear cell infiltration
of the cortex with distruction of tubular cells (X360).
Fig. 2. Alfograft, two weeks post-transplantation, section stained with
hematoxylin and eosin. There is lymphocytic margination on the swollen
and vacuolated endothelium. There are also occasional lymphocytes
within the muscular media, and mild vacuolation of myocytes (X640).
At four weeks the inflammatory changes had mostly subsided.
Infiltration was localized around the big arteries, with some
scattered cells in the interstitium, but with no tubular penetration.
Glomeruli mostly appeared normal, though a few showed in-
creased cellularity. Vascular endothelial cells were prominent but
there were no other abnormalities. Microthrombi, interstitial
edema, and tubular epithelial attenuation had disappeared. Allo-
grafts obtained at six weeks post-transplantation had a similar
picture.
At 10 weeks, the signs of chronic changes were first seen. There
was proliferation of cells in the intima of arcuate and interlobular
arteries, causing significant occlusion of the lumina (Fig. 3).
However, there were no tubular or interstitial changes at this time
point. At 12 weeks the proliferation of the intima continued and
some degree of medial hypertrophy of the arteries was also seen.
At 16 weeks the lumina of some arterioles and arteries were
obviously narrowed and the proliferating cells were mostly re-
placed by fibrous tissue. Tubular atrophy, fibrous expansion of
interstitium, and segmental sclerosis of some glomeruli, were
present. At 20 weeks most parts of the grafts were sclerosed with
occluded or severely narrowed arterial lumina, and obliterated
glomeruli. Tubules were atrophic and irregular, separated by
Fig. 3. Allograft, 10 weeks post-transplantation. There is partial destruc-
tion of the media with severe intimal proliferation, causing partial
occlusion of the artery (X920).
Fig. 4. Allograft, 20 weeks post-transplantation. There is widespread
tubular atrophy and interstitial fibrosis. The lumen of the artery is greatly
narrowed due to intimal hyperplasia (x340).
widely expanded and fibrosed interstitium (Fig. 4). Though the
degree of these changes varied in different grafts and some viable
tubles remained, the general picture was that of irreversible
end-stage damage.
Isografi group. At two weeks very mild tubular epithelial atten-
uation was seen in one of the grafts. This was the only abnormality
observed in this group. Until the dates of sacrifice the grafts
appeared otherwise normal throughout the experimental period.
Graft function
Serum creatinine started to rise in the allograft group at 10
weeks post-transplantation (P < 0.001) and remained high until
the time the rats were killed. In contrast, the creatinine remained
normal in the isograft group during the period of study (P> 0.05;
Fig. 5).
tPA and PA!-! mRNA expression
tPA mRNA was detected in every allo- and isograft. In the
allograft group there was a significant increase in the tPA mRNA
transcripts at two weeks post-transplantation (P < 0.05). It then
reduced to normal at four weeks, and remained at the same level
until the end of the experiment (P > 0.05). There was no
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but mostly restricted to the viable tissue and largely gone from
the sclerosed areas, though there were still a few positive cells in
the sclerosed interstitium. No PAl-i staining was observed in the
isografts, nor in the normal kidneys.
• Fibrin. The monoclonal antibody to fibrin 13 chain was used to
localize fibrin in the tissue [23]. The staining was persistently
positive in all the allografts throughout the period observed. At7 • -- two weeks, fibrin was mostly localized in the pen-tubular capil-
• lanes and the surrounding tissues (Fig. 9A). In some areas, it had
almost blocked the lumina of the capillaries. There was also
: positive staining in some glomeruli, tubular lumina and in the
microthrombi. Some vasa recta in the medulla also showed
positivity. With the progression of the disease, fibrin was more
often seen in the proliferating intima of the arteries (Fig. 9B), with
the same localization as PAl-i antigen, and sometimes on the
0 2 4 6 10 12 16 20 luminal surface of the blood vessels. At the end of the experimen-
tal period, when the allografts were largely sclerosed, fibrin
Week staining was still positive and was localized mostly in the intersti-
tium. In the isografts, there was very rare staining in a few
glomeruli.
DISCUSSION
Persistent fibrin deposition in kidneys undergoing chronic
rejection has been recognized for some time both in experimental
animals [4—61 and humans [7]. Unlike in acute rejection episodes
where thrombotic changes are prominent [24], the abnormality in
the balance between hemostasis and fibrinolysis is more reflected
in the latent and continuous accumulation of fibrin in the vascu-
lature and in the surrounding tissues. The roles of the individual
fibrinolytic components mediating this process are largely un-
known. The present study showed that there was a transient
up-regulation of tPA during the acute phase of rejection that
declined to the normal level afterwards. In contrast, the induction
of PAl-i together with fibrin deposition persisted through to the
development of the chronic changes in the grafts. This suggests
that up-regulation of PM-i, and consequently the imbalance in
the plasminogen inhibitor/activator expression, may favor a de-
cline in fibninolysis, and thus cause the persistence of fibnin in the
grafts.
Vascular endothelial cells, situated at the interface of the
recipient circulation and the donor tissue, are believed to be one
of the main cell types to synthesize tPA and PAl-i [10—14, 24].
They are also one of the first tissues attacked by the recipient
immune system immediately after grafting. tPA is normally ex-
pressed by these cells, forming part of the natural anticoagulant
pathway in the vessel wall. PAl-i expression, on the other hand,
occurs during endothelial cell damage/activation [10—14, 241. In
the present study, the transient up-regulation of tPA during the
early inflammatory period after grafting may reflect the acute
response of these cells to the recipient immune attack, though the
precise mechanisms, and the mechanisms leading to its subse-
quent return to normal, are unknown. The persistent up-regula-
tion of PAl-I observed in the absence of any morphological signs
of active rejection indicates that there was a latent and continuous
assault on the endothelial cells lining the blood vessels, which
eventually led to the obliteration of the vasculature and the
ischemic changes in the renal cortex.
It has also been shown, in vivo and in vitro, that PAl-i interacts
with several components of the cytokine network such as inter-
leukin-1 beta, tumor necrosis factor, transforming growth factor,
etc. [5, 25—32, reviewed in 24]. It is therefore plausible that the
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Fig. 5. Serum creatinine of the transplanted and the normal rats (day 0).
Each dot represents a rat: (•) allograft group; (0) isograft group. The
solid and dotted bars are the median values. Serum creatinine increased in
the allograft group at 10 weeks post-transplantation and remained high
afterwards (P < 0.001).
significant change in the tPA mRNA in the isograft group during
this period (Fig. 6).
PM-i mRNA was exclusively detected in the allografts. Despite
long exposure periods (upto 30 days), no PAl-i mRNA was
detected in any of the isografts (data not shown). There was a
wide variation of the intensity of PAl-i bands in different allo-
grafts, but no significant difference between any of the time points
(Fig. 6).
Immunohistochemical detection of tPA, PA!-! and fibrin
tPA. Immunofluorescence showed that tPA antigen in the
allografts was localized in endothelial cells, notably in glomeruli.
The intensity of staining was generally weak. This could be for two
reasons: (1) tPA has a short half life, and is present in very small
quantities at any given time; (2) the demonstration depended on
cross species reactivity, because the antibody available was anti-
human tPA. The strongest staining was observed at two weeks in
the allograft group (Fig. 7), and then reduced afterwards. At the
end of the experimental period there was still positive, but weak
staining, mostly localized in the remaining viable tissue. tPA
staining in the isografts was even less than in the allografts and
almost identical to normal rats, similar to that reported by
previous investigators [20, 22].
PAl-i. PAT-i staining was positive in all the allografts. In the
early stages of the disease (weeks 2 to 8) PAl-i was mostly
localized to the swollen and vacuolated vascular endothelial cells
of the arteries, veins and capillaries (Fig. 8A). PAT-i staining was
also detected in association with glomerular and peritubular
capillary thrombi. Extracellular matrix staining of irregular PAl-i
positive granules largely occurred around the areas with a heavy
infiltrate. Some scattered interstitial cells were also positive. The
intensity of the staining was strongest at two weeks. From 10
weeks onwards, PAl-i was more localized to the actively prolif-
erating intimal cells of the affected arteries (Fig. 8B), and
sometimes in the Bowman's capsule of the glomeruli. At the end
of the experiment, PAT-I was still positive in every allograft,
up-regulation of PAT-i during the latent progression of rejection
did not only cause reduced removal of fibrin, but also influenced
the tissue response through various cytokines and their growth
factor-like effects. The interesting observation that PAl-i staining
was frequently identified in the proliferating intima of the affected
arteries and arterioles seems to further support the hypothesis
that PAT-i itself is one of the mediators released by the damaged
endothelial cells that perpetuates chronic graft rejection.
In glomerulonephritis and some other forms of glomerular
diseases it has been proposed that fibrin is a strong stimulus to the
epithelial cells lining Bowman's capsule, causing proliferation,
fibrosis, and eventually obliteration of the glomeruli when it leaks
into the Bowman's space [10]. Despite this evidence, the mecha-
nisms and consequences of fibrin deposition in transplant rejec-
tion have not received much attention. However, the organization means [2—9] cast little doubt about its role in obliteration of
and hyalization of deposited fibrin in the vessel walls and in the hollow structures, and the eventual influence on graft failure.
surrounding tissues frequently revealed by histopathological Another interesting feature about this model is the spontaneous
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Fig. 6. RNA extracted from the grafts and the normal rat kidneys (day 0) was hybridized with radiolabeled tPA (upper panel) and PAl-i (lower panel)
probes. The mixture was then subjected to the RNase digestion, separated by gel electrophoresis, and exposed to X-ray films. The upper panel shows
that there was increased tPA expression in the allograft group at two weeks post transplantation. PAL-i transcript band was detected in all the allografts
(lower panel), but not in any of the isografts (data not shown).
Fig. 7. Allograft, two weeks post-transplantation. The section is stained
with fluorescence-labeled anti-human tPA antibody. The glomerulus and
the interstitial capillaries are stained for tPA. The intensity of tPA staining
is reduced from four weeks afterwards (X480).
Fig. 8. (A) Allograft, two weeks post-transplantation stained for PAl-i.
The endothelial cells of the arterioles are prominent and stained for PAl-i
(arrow; x2,900). (B) Allograft, 10 weeks post-transplantation, stained with
anti-PAL-I antibody. Staining of PAT-i (arrow) is localized in the prolif-
erating intima of the artery (arrowhead; X1,100).
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